for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Mithra Pharmaceuticals SA

MITRA.BR

Latest Trade

27.40EUR

Change

-0.46(-1.65%)

Volume

19,824

Today's Range

27.36

 - 

27.88

52 Week Range

18.12

 - 

32.96

As of on the Euronext Brussels ∙ Minimum 15 minute delay

Latest Developments

Mithra Pharmaceuticals: European Authorities Approve Modifications To Myring Labelling

Nov 8 (Reuters) - Mithra Pharmaceuticals SA <MITRA.BR>::EUROPEAN AUTHORITIES APPROVE ADVANTAGEOUS MODIFICATIONS TO MYRING LABELLING.REMOVAL OF REQUIREMENT FOR SPECIAL TEMPERATURE STORAGE FOR VAGINAL CONTRACEPTIVE RING MYRING.COMPETITIVE ADVANTAGE IN TERMS OF REDUCED COSTS AND CONVENIENCE FOR DISTRIBUTORS, PHARMACISTS AND PATIENTS.SHELF-LIFE OF MYRING HAS BEEN EXTENDED FROM 18 TO 24 MONTHS.REQUIREMENT FOR SPECIAL STORAGE CONDITIONS HAS BEEN LIFTED.

Mithra Signs Agreement For Commercialization Of Myring™ In China With Abbott

Oct 14 (Reuters) - MITHRA PHARMACEUTICALS SA <MITRA.BR>::MITHRA SIGNS AGREEMENT FOR COMMERCIALIZATION OF MYRING™ IN CHINA WITH ABBOTT.GRANTS AN EXCLUSIVE LICENSE FOR COMMERCIALIZATION OF VAGINAL CONTRACEPTIVE RING IN CHINA.

Mithra Pharmaceuticals Initiates Phase III Clinical Program For Donesta

Oct 9 (Reuters) - MITHRA PHARMACEUTICALS SA <MITRA.BR>::MITHRA INITIATES PHASE III CLINICAL PROGRAM FOR DONESTA®.PHASE III PROGRAM INCLUDES TWO PIVOTAL STUDIES AIMED AT ENROLLING A TOTAL OF 2200 WOMEN AGED FROM 40 TO 65 YEARS.RECRUITMENT OF THE FIRST PATIENT MARKS LAUNCH CLINICAL PROGRAM FOR DONESTA IN MENOPAUSAL WOMEN WITH VASOMOTOR SYMPTOMS.PHASE III PROGRAM, ENTIRELY FUNDED BY MITHRA, SHOULD BE COMPLETED OVER A PERIOD OF TWO YEARS.BELIEVES IT COULD ACHIEVE MARKETING AUTHORIZATION FOR DONESTA IN 2023.PRIMARY OBJECTIVE TO MEASURE EFFECT OF TREATMENT COMPARED TO PLACEBO AND SEVERITY OF VMS IN MENOPAUSAL WOMEN AT 4 AND 12 WEEKS.SECONDARY OBJECTIVES INCLUDE VALUATION OF TREATMENT EFFECT ON ADDITIONAL KEY EFFICACY AND SAFETY PARAMETERS.ONGOING PATENT APPLICATIONS WOULD PROTECT DONESTA INTELLECTUAL PROPERTY RIGHTS UNTIL 2039.

Mithra Provides Supplementary Details On Estelle® Us Deal With Mayne

Oct 3 (Reuters) - MITHRA PHARMACEUTICALS SA <MITRA.BR>::MITHRA PROVIDES SUPPLEMENTARY DETAILS ON ESTELLE® US DEAL WITH MAYNE.WILL RECEIVE MINIMUM OF USD 295 MILLION IN LICENSE FEES, COMPRISED OF MILESTONE FEES IN CASH AND IN EQUITY.UNDER TERMS OF 20-YEAR AGREEMENT, MITHRA WILL RECEIVE: FIXED SUPPLY PRICE PER PRODUCT.MITHRA PHARMACEUTICALS SA <<<MITRA.BR>>> - UNDER TERMS OF 20-YEAR AGREEMENT, MITHRA WILL RECEIVE: VARIABLE SUPPLY PRICE BASED ON A PERCENTAGE (HIGH DOUBLE-DIGITS) OF NET SALES.

Mithra Pharmaceuticals Renegotiates Earnout Payments

Oct 1 (Reuters) - MITHRA PHARMACEUTICALS SA <MITRA.BR>::MITHRA SUCESSFULLY RENEGOTIATES EARNOUT PAYMENTS.REMAINING PAYMENT OBLIGATIONS TO UTERON PHARMA REDUCED BY 62% TO EUR 250 MILLION.TOTAL PAYMENT DURATION REDUCED BY TWELVE YEARS.SUBSTANTIAL REDUCTION OF TOTAL DEBT UNDER IFRS.OPTION FOR MITHRA TO PAY EUR 40 MILLION CASH TRANCHE IN EQUITY.SIGNIFICANT CASH FLOW IMPROVEMENT SAFEGUARDING DEVELOPMENT OF ESTELLE® AND DONESTA.MITHRA WILL MAKE A LUMP SUM PAYMENT OF EUR 250 MILLION IN TOTAL OVER A PERIOD OF 9 YEARS.FUTURE PAYMENTS TO UTERON PHARMA WILL BE CONDITIONED TO REMAINING CASH POSITION POST EARNOUT PAYMENT, SUFFICIENT TO COVER COST OF DEVELOPMENT OF ESTELLE AND DONESTA.REMAINING EUR 210 MILLION CASH AMOUNT WILL BE PAYABLE IN NINE ANNUAL INSTALMENTS BEGINNING IN 2021, ONCE ESTELLE® IS COMMERCIALIZED.NEW FAIR VALUE OF OUR CONTINGENT CONSIDERATIONS WILL BE SIGNIFICANTLY REDUCED TO AROUND EUR 150 MILLION, IMPLYING A POSITIVE IMPACT ON INCOME STATEMENT.EUR 25 MILLION MILESTONE PAYMENT DUE AT FDA APPROVAL HAS NOW BEEN SUPRESSED.

Mithra Signs Landmark Contract For Estelle® With Mayne Pharma

Oct 1 (Reuters) - MITHRA PHARMACEUTICALS SA <MITRA.BR>::MITHRA SIGNS LANDMARK CONTRACT FOR ESTELLE® IN THE UNITED STATES WITH MAYNE PHARMA.MITHRA ELIGIBLE FOR LICENSE FEES OF AT LEAST USD 295 MILLION.MITHRA TO BE AWARDED 9.6% EQUITY STAKE ACROSS TWO TRANCHES IN MAYNE PHARMA.POTENTIAL GROSS REVENUES IN MITHRA'S WORST-CASE SCENARIO AT A MINIMUM OF EUR 4,5 BILLION, WHICH REPRESENTS MORE THAN TWICE SIZE OF EUROPEAN DEAL.CDMO CROSS FERTILIZATION OPPORTUNITIES FOR BOTH COMPANIES.PARTIES WILL WORK TOGETHER ON REGULATORY SUBMISSION PLANNED BY END 2019 WITH PROJECTED COMMERCIAL LAUNCH OF ESTELLE® IN H1 2021.

Mithra Pharmaceuticals H1 Net Loss Widens To EUR 89.7 Mln

Sept 19 (Reuters) - Mithra Pharmaceuticals SA <MITRA.BR>::H1 RESULTS.H1 GROUP TOTAL REVENUE EUR 19.6 MILLION VERSUS EUR 12.6 MILLION YEAR AGO.H1 GROUP TOTAL NET LOSS FOR THE PERIOD EUR 89.7 MILLION VERSUS LOSS OF EUR 34.4 MILLION YEAR AGO.H1 GROUP TOTAL OPERATING LOSS EUR 5.0 MILLION VERSUS LOSS OF EUR 12.9 MILLION YEAR AGO.END-H1 CASH POSITION AT EUR 77.5 MILLION.

Mithra Signs LSA For Commercialization Of Estelle, Myring In Israel

Aug 20 (Reuters) - Mithra Pharmaceuticals SA <MITRA.BR>::MITHRA SIGNS LSA FOR COMMERCIALIZATION OF ESTELLE® AND MYRING™ IN ISRAEL.UNDER TERMS OF THESE AGREEMENTS, DEXCEL WILL DISTRIBUTE ESTELLE® AND MYRING™ IN ISRAEL.MITHRA GRANTS EXCLUSIVE LICENSE TO DEXCEL PHARMA FOR COMMERCIALIZATION OF ITS TWO LEADING CONTRACEPTIVE PRODUCTS IN ISRAEL.

Mithra Obtains Additional Estelle Patent In Japan

Aug 8 (Reuters) - Mithra Pharmaceuticals SA <MITRA.BR>::MITHRA OBTAINS CRUCIAL ADDITIONAL ESTELLE® PATENT IN JAPAN.ESTELLE® WILL BE PROTECTED FROM ANY GENERIC COMPETITOR ON JAPANESE MARKET UNTIL 2037 WITH A POTENTIAL PATENT TERM EXTENSION OF A MAXIMUM OF 5 YEARS.

Mithra Pharmaceuticals Signs LSA For Commercialization Of Myrin In Germany

May 28 (Reuters) - MITHRA PHARMACEUTICALS SA <MITRA.BR>::THIS AGREEMENT COULD GENERATE REVENUES OF AT LEAST EUR 2.5 MILLION FOR MITHRA.MITHRA SIGNS LSA FOR COMMERCIALIZATION OF MYRING IN GERMANY, THE BIGGEST MARKET IN EUROPE.UNDER TERMS OF THIS 5-YEAR AGREEMENT, HORMOSAN WILL DISTRIBUTE MYRING IN GERMANY.COMMERCIAL MANUFACTURING PROCESS WILL CONTINUE IN SECOND HALF OF YEAR FOR COMMERCIAL BATCHES FOR EUROPEAN MARKET.MITHRA WILL RECEIVE AN UPFRONT PAYMENT AND WILL BE ELIGIBLE TO RECEIVE MILESTONE PAYMENTS AND RECURRING REVENUES BASED ON MINIMUM ANNUAL QUANTITIES (MAQ).

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up